Market capitalization | €446.52m |
Enterprise Value | €323.40m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.51 |
Revenue (TTM) Revenue | €0.00 |
EBIT (operating result TTM) EBIT | €-179.27m |
Free Cash Flow (TTM) Free Cash Flow | €-154.77m |
EPS (TTM) EPS | €-3.28 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Abivax SA forecast:
8 Analysts have issued a Abivax SA forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.95 -0.95 |
164%
164%
|
|
EBITDA | -178 -178 |
131%
131%
|
EBIT (Operating Income) EBIT | -179 -179 |
131%
131%
|
Net Profit | -177 -177 |
92%
92%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development comprise of vaccine for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Head office | France |
CEO | Marc Garidel |
Employees | 61 |
Founded | 2013 |
Website | www.abivax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.